Product news

Schering-Plough said the FDA has approved label revisions for Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin, USP) combination therapy for chronic hepatitis C, recommending weight-based dosing of Rebetol (800-1400 mg daily) based on patient body weight.

March 27, 2008

5:56 pm

Schering-Plough said the FDA has approved label revisions for Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin, USP) combination therapy for chronic hepatitis C, recommending weight-based dosing of Rebetol (800-1400 mg daily) based on patient body weight. The revised label also recommends a shorter, 24-week course of the combination therapy for patients with chronic hepatitis C virus genotype 2 or 3.

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.